Skip to content
zameds

Lurasidone (Latumak, Maktuda)

Lurasidone

Macleods Pharmaceuticals SA (Pty) Ltd

S5Read from the PI-PIL document and verified

Registration

Applicant
Macleods Pharmaceuticals SA (Pty) Ltd
Certificate holder
Macleods Pharmaceuticals SA (Pty) Ltd
Registrations
10
Schedule source
SAHPRA documentation

Variants

ProductStrength and formRegistrationStatusScheduleLeaflets
Latumak 20 MG

EACH TABLET CONTAINS LURASIDONE HYDROCHLORIDE 20,0 mg

20 mgFilm coated tablet57076757/1.2/0767Approved 27 August 2024RegisteredS5PIPIL
Latumak 40 MG

EACH TABLET CONTAINS LURASIDONE HYDROCHLORIDE 40,0 mg

40 mgFilm coated tablet57076857/1.2/0768Approved 27 August 2024RegisteredS5PIPIL
Latumak 60 MG

EACH TABLET CONTAINS LURASIDONE HYDROCHLORIDE 60,0 mg

60 mgFilm coated tablet57076957/1.2/0769Approved 27 August 2024RegisteredS5PIPIL
Latumak 80 MG

EACH TABLET CONTAINS LURASIDONE HYDROCHLORIDE 80,0 mg

80 mgFilm coated tablet57077057/1.2/0770Approved 27 August 2024RegisteredS5PIPIL
Latumak 120 MG

EACH TABLET CONTAINS LURASIDONE HYDROCHLORIDE 120,0 mg

120 mgFilm coated tablet57077157/1.2/0771Approved 27 August 2024RegisteredS5PIPIL
Maktuda 20 MG

EACH TABLET CONTAINS LURASIDONE HYDROCHLORIDE 20,0 mg

20 mgFilm coated tablet570772.76757/1.2/0772.767Approved 27 August 2024RegisteredNot determinedPIPIL
Maktuda 40 MG

EACH TABLET CONTAINS LURASIDONE HYDROCHLORIDE 40,0 mg

40 mgFilm coated tablet570773.76857/1.2/0773.768Approved 27 August 2024RegisteredNot determinedPIPIL
Maktuda 60 MG

EACH TABLET CONTAINS LURASIDONE HYDROCHLORIDE 60,0 mg

60 mgFilm coated tablet570774.76957/1.2/0774.769Approved 27 August 2024RegisteredNot determinedPIPIL
Maktuda 80 MG

EACH TABLET CONTAINS LURASIDONE HYDROCHLORIDE 80,0 mg

80 mgFilm coated tablet570775.77057/1.2/0775/770Approved 27 August 2024RegisteredNot determinedPIPIL
Maktuda 120 MG

EACH TABLET CONTAINS LURASIDONE HYDROCHLORIDE 120,0 mg

120 mgFilm coated tablet570776.77157/1.2/0776.771Approved 27 August 2024RegisteredNot determinedPIPIL

Regulatory status

Where S5 sits on the scale

Prescription-only, with tighter controls on repeats.

Schedule 5 medicines need a prescription, and repeat dispensing is capped at six months in total; the prescriber must state upfront how many times, and at what intervals, it may be repeated. Extra limits apply to some uses: if it is being used for its anxiolytic, antidepressant, tranquillising or analgesic properties, it cannot be prescribed for longer than six months without a further consultation. Its price, name, pack size and strength can still be told to the public, as long as nothing links it to what it treats.

Schedule S5, read from the product's PI-PIL leaflet.

The Consolidated Schedules list this ingredient up to S4; the leaflet's S5 applies to this product.

Who may supply: A pharmacist dispensing against a written or verbal prescription from an authorised prescriber; a veterinarian, who may also prescribe, compound or dispense it directly; a medical practitioner or dentist, who may prescribe it and may compound or dispense it directly only if licensed under section 22C(1)(a); manufacturers and wholesalers may supply people who may lawfully possess it.

Consolidated Schedules listings for Lurasidone hydrochloride

  • S4: Lurasidone

    Consolidated Schedules 06 July 2026, line 6978

Pharmacological class: Psychoanaleptics (antidepressants). (class 1.2)

5 of 5 approved products with this ingredient carry S5 on their leaflet.

This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.

C28H36N4O2S492.70 g/mol

(1R,2S,6R,7S)-4-[[(1R,2R)-2-[[4-(1,2-Benzothiazol-3-yl)piperazin-1-yl]methyl]cyclohexyl]methyl]-4-azatricyclo[5.2.1.02,6]decane-3,5-dione

Drag to rotate. Structure from PubChem CID 213046.

SAHPRA documents

Schedule verified from official documents

Schedule Verification

This medication's schedule (S5) has been verified from official SAHPRA documents with 90% confidence.

Professional information (PI)For healthcare professionalsPatient information leaflet (PIL)For patients and carers

These documents are provided by SAHPRA for informational purposes. Always consult with a healthcare professional for medical advice.

Background

Loading...
Loading Wikipedia summary

Research articles

Loading...
Loading PubMed articles